References
- Simon TG, Schneeweiss S, Singer D, Sreedhara SK, Lin KJ. Prescribing trends of oral anticoagulants in US patients with cirrhosis and nonvalvular atrial fibrillation. J Am Heart Assoc. 2023 Feb 7;12(3):
e026863 . doi: 10.1161/JAHA.122.026863 - Van der Wall S, Hendriks S, Huisman, Menno, Klok FA. Home treatment of acute pulmonary embolism: state of the art in 2018. Curr Opin Pulm Med. 2018 Sep;24(5):425–431. doi: 10.1097/MCP.0000000000000512
- Kuhrau S, Masic D, Manci E, et al. Impact of pulmonary embolism response team on anticoagulation prescribing patterns in patients with acute pulmonary embolism. J Pharm Pract. 2022 Feb;35(1):38–43. doi: 10.1177/0897190020940125
- Rivera-Lebron BN, Rali PM, Tapson VF. The PERT concept: a step-by-step approach to managing pulmonary embolism antithrombotic therapy for vte disease: second update of the CHEST guideline and expert panel report. Chest. 2021 Jan;159(1):347–355. doi: 10.1016/j.chest.2020.07.065
- Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021 Dec;160(6): e545–e608. doi: 10.1016/j.chest.2021.07.055
- Tapson VF, Sterling K, Jones N, et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: The OPTALYSE PE trial. JACC Cardiovasc Interv. 2018 Jul 23;11(14):1401–1410. doi: 10.1016/j.jcin.2018.04.008
- Roy PM, Douillet D, Penaloza A. Contemporary management of acute pulmonary embolism Trends. Cardiovasc Med. 2022 Jul;32(5):259–268. doi: 10.1016/j.tcm.2021.06.002
- Prandoni P. Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study. Eur J Haematol. 2012 Oct;89(4):281–7. doi: 10.1111/ejh.12002
- Panahi L, Udeani G, Horseman M, et al. Review of medical therapies for the management of pulmonary embolism. Medicina (Kaunas). 2021 Jan 26;57(2):110. doi: 10.3390/medicina57020110
- Freund Y, Cohen-Aubart F, Bloom B. Acute pulmonary embolism: a review. JAMA. 2022 Oct 4;328(13):1336–1345. doi: 10.1001/jama.2022.16815
- Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543–603. doi: 10.1093/eurheartj/ehz405
- Dix C, Tran H. Pulmonary embolus. Aust J Gen Pract. 2022 Sep;51(9):667–671. doi: 10.31128/AJGP-05-22-6440
- Duffett L, Castellucci LA, Forgie MA. Pulmonary embolism: update on management and controversies. BMJ. 2020 Aug 5:370:
m2177 . doi: 10.1136/bmj.m2177 - Goldhaber SZ, Eriksson H, Kakkar A, et al. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™. Vasc Med. 2016 Dec;21(6):506–514. doi: 10.1177/1358863X16668588
- Zuily S, Cohen H, Isenberg D, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020 Sep;18(9):2126–2137. doi: 10.1111/jth.14935
- Rosovsky RP, Kline-Rogers E, Lake L, et al. Direct Oral Anticoagulants in Obese Patients with Venous Thromboembolism: Results of an Expert Consensus Panel. Am J Med. 2023 Jun;136(6):523–533. doi: 10.1016/j.amjmed.2023.01.010
- Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet. 2021 Jul 3;398(10294):64–77. doi: 10.1016/S0140-6736(20)32658-1
- Lubetsky A. Pulmonary Embolism in Cancer Patients: A Review. Isr Med Assoc J. 2022 Mar;24(3):179–182. PMID: 35347932
- Mi YH, Xu MY. Trauma-induced pulmonary thromboembolism: What’s update? Chin J Traumatol. 2022 Mar;25(2):67–76. doi: 10.1016/j.cjtee.2021.08.003
- Carman TL. Anticoagulation Beyond 3 to 6 Months: What Does the Data Tell Us? Prog Cardiovasc Dis. 2018 Mar–Apr;60(6):607–612. doi: 10.1016/j.pcad.2018.04.002
- Chang H, Kim MS, Lee SY, et al. Does anticoagulation needed for distally located incidental pulmonary thromboembolism in patients with active cancer? PLoS One. 2019 Sep 12;14(9):
e0222149 . doi: 10.1371/journal.pone.0222149 - Agnelli G, Buller HR, Cohen A, et al. AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699–708. doi: 10.1056/NEJMoa1207541
- Weitz JI, Lensing AWA, Prins MH, et al. EINSTEIN CHOICE Investigators. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017 Mar 30;376(13):1211–1222. doi: 10.1056/NEJMoa1700518
- Birocchi S, Scannella E, Ferrari L, Podda GM; Gruppo di Autoformazione Metodologica (GrAM). Aspirin in the secondary prevention of unprovoked thromboembolism: the WARFASA and ASPIRE studies. Intern Emerg Med. 2013 Dec;8(8):757–60. doi: 10.1007/s11739-013-0961-7
- Becattini C, Agnelli G, Schenone A, et al.; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012 May 24;366(21):1959–67. doi: 10.1056/NEJMoa1114238
- Prandoni P, Noventa F, Milan M. Aspirin and recurrent venous thromboembolism. Phlebology. 2013 Mar;28 Suppl 1:99–104. doi: 10.1177/0268355512475040
- Andreozzi GM, Bignamini AA, Davì G, et.al. SURVET Study Investigators. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Circulation. 2015 Nov 17;132(20):1891–7. doi: 10.1161/CIRCULATIONAHA.115.016930
- Jiang QJ, Bai J, Jin J, Shi J, Qu L. Sulodexide for Secondary Prevention of Recurrent Venous Thromboembolism: A Systematic Review and Meta-Analysis. Front Pharmacol. 2018 Aug 8;9:876. doi: 10.3389/fphar.2018.00876
- Errichi BM, Cesarone MR, Belcaro G, et al. Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry. Angiology. 2004 May–Jun;55(3):243–9. doi: 10.1177/000331970405500302
- Ruiz IF. Anticoagulation therapy: Sulodexide reduces the risk of recurrent venous thromboembolism. Nat Rev Cardiol. 2015 Dec;12(12):682. doi: 10.1038/nrcardio.2015.163
- Kakkar VV, Gebska M, Kadziola Z, Saba N, Carrasco P; Bemiparin Investigators. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost. 2003 Apr;89(4):674–80. PMID: 12668122
- Romera A, Cairols MA, Vila-Coll R, et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg. 2009 Mar;37(3):349–56. doi: 10.1016/j.ejvs.2008.11.030
- Piati PK, Peres AK, de Andrade DO, Jorge MA, Toregeani JF. Analysis of recanalization of deep venous thrombosis: a comparative study of patients treated with warfarin vs. rivaroxaban. J Vasc Bras. 2019 Jun 17;18:
e20180111 . doi: 10.1590/1677-5449.180111 - Robin P, Le Pennec R, Eddy M, et al. Residual pulmonary vascular obstruction and recurrence after acute pulmonary embolism: a systematic review and meta-analysis of individual participant data. J Thromb Haemost. 2023 Jun;21(6):1519–1528.e2. doi: 10.1016/j.jtha.2023.01.030
- Aranda C, Peralta L, Gagliardi L, López A, Jiménez Á, Herreros B. A significant decrease in D-dimer concentration within one month of anticoagulation therapy as a predictor of both complete recanalization and risk of recurrence after initial pulmonary embolism. Thromb Res. 2021 Jun;202:31–35. doi: 10.1016/j.thromres.2021.02.033
- Martin KA, Cuttica MJ. Chronic thromboembolic pulmonary hypertension: anticoagulation and beyond. Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):478–484. doi: 10.1182/hematology.2021000282
- Cazaubon M, Benigni JP, Steinbruch M, Jabbour V, Gouhier-Kodas C. Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence. Vasc Health Risk Manag. 2021 Sep 16;17:591–600. doi: 10.2147/VHRM.S324112
- Bouskela E, Lugli M, Nicolaides A. New Perspectives on Micronised Purified Flavonoid Fraction in Chronic Venous Disease: From Microvalves to Clinical Effectiveness. Adv Ther. 2022 Oct;39(10):4413–4422. doi: 10.1007/s12325-022-02218-x
- Naoum JJ, Hunter GC. Pathogenesis of varicose veins and implications for clinical management. Vascular. 2007 Sep–Oct;15(5):242–9. doi: 10.2310/6670.2007.00069
- Tsimoyiannis EC, Floras G, Antoniou N, Papanikolaou N, Siakas P, Tassis A. Low-molecular-weight heparins and Daflon for prevention of postoperative thromboembolism. World J Surg. 1996 Oct;20(8):968–71; discussion 972. doi: 10.1007/s002689900145
- Kuznetsov MR, Sapelkin SV, Boldin BV, Leont’ev SG, Neskhodimov LA. [Recanalization of lower-limb deep veins as an index of efficacy of treatment for acute venous thrombosis]. Angiol Sosud Khir. 2016;22(3):82–8. PMID: 27626254
- Lobastov K, Schastlivtsev I, Barinov V. Use of Micronized Purified Flavonoid Fraction Together with Rivaroxaban Improves Clinical and Ultrasound Outcomes in Femoropopliteal Venous Thrombosis: Results of a Pilot Clinical Trial. Adv Ther. 2019 Jan;36(1):72–85. doi: 10.1007/s12325-018-0849-z
- Schastlivtsev I, Lobastov K, Barinov V, Kanzafarova I. Diosmin 600 in adjunction to rivaroxaban reduces the risk of post-thrombotic syndrome after femoropopliteal deep vein thrombosis: results of the RIDILOTT DVT study. Int Angiol. 2020 Oct;39(5):361–371. doi: 10.23736/S0392-9590.20.04356-4
DOI: https://doi.org/10.14797/mdcvj.1338 | Journal eISSN: 1947-6108
Language: English
Page range: 27 - 35
Submitted on: Jan 9, 2024
Accepted on: Feb 27, 2024
Published on: May 16, 2024
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2024 Joseph J. Naoum, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.